ChromaDex added to membership of US small-cap Russell 2000® Index
June 25 2018 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based,
nutraceutical company devoted to improving the way people age with
its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®,
announced today it was added as a member of the US small-cap
Russell 2000® Index, effective after the US market opens on
June 25, as part of the 2018 Russell indexes reconstitution.
Membership in the Russell 2000® Index, which
remains in place for one year, is based on membership in the
broad-market Russell 3000® Index. The stock also was
automatically added to the appropriate growth and value
indexes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets
are benchmarked against Russell’s US indexes. Russell indexes are
part of FTSE Russell, a leading global index provider.
For more information on the Russell 2000® Index and the
Russell indexes reconstitution, go to the “Russell Reconstitution”
section on the FTSE Russell website.
About ChromaDex:ChromaDex
Corp. is an integrated, global nutraceutical company devoted to
improving the way people age. ChromaDex scientists partner with
leading universities and research institutions worldwide to uncover
the full potential of NAD and identify and develop novel,
science-based ingredients. Its flagship ingredient,
NIAGEN® nicotinamide riboside, sold directly to consumers as
TRU NIAGEN®, is backed with clinical and scientific research, as
well as extensive IP protection. TRU NIAGEN® is helping the
world AGE BETTER®. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
About FTSE Russell:FTSE
Russell is a leading global index provider creating and managing a
wide range of indexes, data and analytic solutions to meet client
needs across asset classes, style and strategies. Covering 98% of
the investable market, FTSE Russell indexes offer a true picture of
global markets, combined with the specialist knowledge gained from
developing local benchmarks around the world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $16.2
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell
indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by London Stock
Exchange Group.
For more information, visit www.ftserussell.com
Forward-Looking Statements:Statements that are
not a description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. More detailed information
about ChromaDex and the risk factors that may affect the
realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal
year ended December 30, 2017, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted
by ChromaDex to the SEC, copies of which may be
obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement
and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a
portion of the grant funding as a collaborator for the study.
ChromaDex Investor Relations Contact: Andrew
Johnson, Director of Investor Relations 949-419-0288
andrewj@chromadex.com
ChromaDex Media Contact: Alex Worsham, Director
of Strategic Partnerships 949-648-3775
alexw@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024